Get started
Work

A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer

Year: 2022
Type: article
Study design: Observational Study
Abstract: Aim: This study examined circulating cell-free DNA (cfDNA) biomarkers associated with androgen treatment resistance in metastatic castration resistance prostate cancer (mCRPC). Materials & methods: We designed a panel of nine candidate cfDNA methylation markers using droplet digital PCR (Methyl-ddPCR) and assessed methylation levels in sequentially collected cfDNA samples from patients with mCRPC. Results: Increased cfDNA methylation in eight out of nine markers during androgen-targeted treatment correlated with a faster time to clinical progression. Cox proportional hazards modeling and logistic regression analysis further confirmed that higher cfDNA methylation during treatment was significantly associated with clinical progression. Conclusion: Overall, our findings have revealed a novel methylated cfDNA marker panel that could aid in the clinical management of metastatic prostate cancer.
Source: Epigenomics
DOI: 10.2217/epi-2022-0103
Authors: Madonna R Peter, Misha Bilenky, Yuliang Shi, Jiajie Pu, Shivani Kamdar, Aaron R Hansen, Neil E Fleshner, Srikala S Sridhar, Anthony M Joshua, Martin Hirst, Wei Xu, Bharati Bapat
Institutions: University of Toronto, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, BC Cancer Agency, Canada's Michael Smith Genome Sciences Centre, University Health Network, Princess Margaret Cancer Centre, The Kinghorn Cancer Centre, University of British Columbia
Language: English
Subfield: Cancer Research
Open Access status: hybrid
OpenAlex ID: W4285077403
FWCI: 0.698
Cites: 35
Cited by: 8
Related to: 10